Tagraxofusp

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication used for the treatment of blastic plasmacytoid dendritic cell neoplasm. It is a CD123-directed cytotoxin. The most common adverse reactions include capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase.

The most common laboratory abnormalities include decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST. Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.

The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its diphtheria toxin portion inhibiting eukaryotic elongation factor 2). It was approved for medical use in the United States in 2018, and in the European Union in January 2021.

The US Food and Drug Administration considers it to be a first-in-class medication.

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication used for the treatment of blastic plasmacytoid dendritic cell neoplasm. It is a CD123-directed cytotoxin. The most common adverse reactions include capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase.

The most common laboratory abnormalities include decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST. Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.

The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its diphtheria toxin portion inhibiting eukaryotic elongation factor 2). It was approved for medical use in the United States in 2018, and in the European Union in January 2021.

The US Food and Drug Administration considers it to be a first-in-class medication.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1356752448 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

9 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.